Ovulation Induction: FSH administered IM/SC with HCG for ovulation induction in women with prior pituitary suppression.
Multiple Follicular Development (ART): Controlled ovarian stimulation during ART cycles with FSH + HCG.
Polycystic Ovarian Syndrome (PCOS): Treatment of infertility related to PCOS.
Male Infertility: In combination with HCG for induction of spermatogenesis in men with hypogonadotropic hypogonadism.

Contains highly purified human FSH (FSH‑HP) derived from urine of postmenopausal women.
Third‑generation urinary gonadotrophins with minimal LH (<0.1%) and proteins (<5%).
Glycoprotein hormone with α and β subunits, carbohydrate‑modified.
Supplied as sterile lyophilized powder for SC/IM injection after reconstitution with 0.9% NaCl.
Each vial contains 75 IU FSH.

Women (Ovulation Induction): Start 50 IU daily SC/IM for ≥7 days; increase by 25–50 IU weekly until adequate response. Final maturation with 5000–10,000 IU HCG.
Women (ART): Start 150–225 IU daily IM for ≥4 days; adjust based on ultrasound/estradiol. Final maturation with 5000–10,000 IU HCG; oocyte retrieval 34–36 hrs later.
PCOS: Start 50 IU daily IM; adjust cautiously (increments 75–225 IU).
Men (Spermatogenesis): Pretreat with HCG 500–3000 IU twice weekly until testosterone normalizes; then add FSH 150–225 IU SC weekly in divided doses.

Ovarian hyperstimulation (pelvic pain, breathing difficulty, fluid in lungs, blood clots).
Multiple births possible.
Common: headache, vaginal bleeding, nausea, hot flushes, injection site reactions.